SNDX vs. PTGX, AMPH, DYN, ENTA, JAZZ, BPMC, IONS, OGN, BBIO, and CYTK
Should you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include Protagonist Therapeutics (PTGX), Amphastar Pharmaceuticals (AMPH), Dyne Therapeutics (DYN), Enanta Pharmaceuticals (ENTA), Jazz Pharmaceuticals (JAZZ), Blueprint Medicines (BPMC), Ionis Pharmaceuticals (IONS), Organon & Co. (OGN), BridgeBio Pharma (BBIO), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical preparations" industry.
Syndax Pharmaceuticals (NASDAQ:SNDX) and Protagonist Therapeutics (NASDAQ:PTGX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.
Protagonist Therapeutics' return on equity of 43.42% beat Syndax Pharmaceuticals' return on equity.
Syndax Pharmaceuticals currently has a consensus price target of $34.42, suggesting a potential upside of 78.60%. Protagonist Therapeutics has a consensus price target of $38.00, suggesting a potential upside of 34.99%. Given Syndax Pharmaceuticals' higher probable upside, equities research analysts plainly believe Syndax Pharmaceuticals is more favorable than Protagonist Therapeutics.
In the previous week, Syndax Pharmaceuticals and Syndax Pharmaceuticals both had 4 articles in the media. Syndax Pharmaceuticals' average media sentiment score of 1.47 beat Protagonist Therapeutics' score of 0.71 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.
98.6% of Protagonist Therapeutics shares are held by institutional investors. 4.1% of Syndax Pharmaceuticals shares are held by insiders. Comparatively, 5.4% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Syndax Pharmaceuticals has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500.
Protagonist Therapeutics has lower revenue, but higher earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.
Syndax Pharmaceuticals received 107 more outperform votes than Protagonist Therapeutics when rated by MarketBeat users. Likewise, 64.79% of users gave Syndax Pharmaceuticals an outperform vote while only 59.73% of users gave Protagonist Therapeutics an outperform vote.
Summary
Protagonist Therapeutics beats Syndax Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Syndax Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syndax Pharmaceuticals Competitors List
Related Companies and Tools
